Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Estring Clear all
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales

NCT02210702
View directory record Official record
Conditions
Postpartum Depressive Mood, Postpartum Sexual Function
Interventions
Ethinyl Estradiol 35mcg/Norethindrone 1mg, Ethinyl Estradiol 20mcg/Norethindrone 1mg
Drug
Lead sponsor
The Jones Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

NCT01182194
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 24, 2026, 2:21 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Optimizing Ovulation Induction in the Poor Responder

NCT01200537
View directory record Official record
Conditions
IVF Poor Responders
Interventions
Estradiol, Oral Contraceptive Pills (OCP)
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

NCT03432416
View directory record Official record
Conditions
Healthy Women, Female Contraception
Interventions
NES-E2 CVR
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 24, 2026, 2:21 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

NCT00565916
View directory record Official record
Conditions
Postmenopausal Syndrome
Interventions
Estrogen, Progesterone, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Early Phase 1 Interventional

Mediators of Abnormal Reproductive Function in Obesity (MARO)

NCT01817400
View directory record Official record
Conditions
Infertility, Female, Obesity
Interventions
Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
Other · Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women

NCT06308614
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Estetrol, Placebo
Drug · Other
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills

NCT03418363
View directory record Official record
Conditions
Contraceptive Usage, Coagulation
Interventions
DHEA Oral Capsule, Placebo Oral Capsule
Dietary Supplement · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 24, 2026, 2:21 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 24, 2026, 2:21 PM EDT
Recruiting Phase 2 Interventional

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

NCT05933395
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Fulvestrant, Neratinib, Alpelisib, Everolimus, Abemaciclib
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women

NCT00141557
View directory record Official record
Conditions
Menopause
Interventions
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
78
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2008 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

NCT03633331
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
447
States / cities
Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Terminated Not applicable Interventional

Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery

NCT00123539
View directory record Official record
Conditions
Coronary Disease, Cardiovascular Diseases, Heart Diseases, Neurologic Manifestations
Interventions
Estrogen Replacement Therapy, Surgery
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
55 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Early Phase 1 Interventional

Gender Disparity and Hormones in Cystic Fibrosis

NCT02036879
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
Loestrin (norethindrone acetate and ethinyl estradiol)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 24, 2026, 2:21 PM EDT
Active, not recruiting Phase 2 Interventional

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions
Alpelisib, Fulvestrant, Aromatase inhibitor
Drug
Lead sponsor
Marina N Sharifi
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NCT05538689
View directory record Official record
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects

NCT03783897
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EDP-305, Oral Contraceptive
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.

NCT02668796
View directory record Official record
Conditions
Vulvar and Vaginal Atrophy
Interventions
Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk), Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Mahwah, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Not applicable Interventional Results available

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

NCT02524769
View directory record Official record
Conditions
Overactive Bladder
Interventions
conjugated estrogen
Drug
Lead sponsor
Loyola University
Other
Eligibility
55 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 24, 2026, 2:21 PM EDT
Terminated Phase 2 Interventional Results available

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

NCT05554354
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
192
States / cities
Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 24, 2026, 2:21 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Reproductive Hormones on Mood and Behavior

NCT00001322
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 24, 2026, 2:21 PM EDT